The Monocyte/High Density Lipoprotein Cholesterol Ratio (MHR) as an Indicator of the Need for Amputation in Patients With Peripheral Artery Disease Developing Critical Limb Ischemia
Restricted accessResearch articleFirst published online March, 2021
The Monocyte/High Density Lipoprotein Cholesterol Ratio (MHR) as an Indicator of the Need for Amputation in Patients With Peripheral Artery Disease Developing Critical Limb Ischemia
The monocyte/high density lipoprotein cholesterol ratio (MHR) reflects the proatherogenic and antiatherogenic balance, and a high ratio is associated with the severity of atherosclerosis. We measured the MHR of patients with critical limb ischemia (CLI) due to peripheral artery disease (PAD) requiring amputation. Patients diagnosed with PAD were divided into 2 groups; those who underwent an amputation due to CLI without any sign of infection and those treated with surgical or percutaneous revascularization or followed up medically. A healthy control group was also included. In patients diagnosed with PAD (n = 563), the MHR value was higher for the control group (n = 200), (12.4 ± 0.42 vs 11.5 ± 0.28, P < .001). In the amputation group, the MHR was significantly higher for the group treated by other methods (15.7 ± 1.52 vs 12.8 ± 1.45, P < .001). Possible confounding factors affecting the MHR value were determined by the univariate regression analysis, and the multiple regression analysis revealed that MHR was an independent predictor of amputation in patients with PAD (P < .001). This study suggests that the MHR may be the predictor of amputation risk in patients with PAD and CLI.
PatelMRConteMSCutlipDE, et al.Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–41.
2.
CookeJPLosordoDW. Modulating the vascular response to limb ischemia: Angiogenic and cell therapies. Circ Res. 2015;116:1561–78.
3.
HirschATHaskalZJHertzerNR, et al.ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113:463-654.
4.
AboyansVRiccoJBBartelinkMEL, et al.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39:763–816.
5.
KanbayMSolakYUnalHU, et al.Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46(8):1619-1625.
6.
LibbyP. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–51.
7.
ZhangYLiSGuoYL, et al.Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med. 2016;48:305–12.
8.
SampsonUKFowkesFGMcDermottMM, et al.Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob Heart. 2014;9:145–58.
9.
FowkesFGAboyansVFowkesFJ, et al.Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14:156–70.
10.
FarberA. Chronic limb-threatening ischemia. N Engl J Med. 2018;379:171–80.
11.
NehlerMRDuvalSDiaoL, et al.Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60:686–95.e2.
12.
HowardDPBanerjeeAFairheadJF, et al.Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation. 2015;132:1805–15.
13.
DaviesMG. Critical limb ischemia: epidemiology. Methodist DeBakey Cardiovasc J. 2012;8:10–14.
14.
KudoTChandraFAKwunWH, et al.Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. J Vasc Surg. 2006;44:304–13.
15.
SwirskiFKNahrendorfM. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161–6.
16.
MooreKJKoplevSFisherEA, et al.Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2). J Am Coll Cardiol. 2018;72:2181–97.
17.
LibbyPRidkerPMMaseriA. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
18.
SignorelliSAnzaldiMFioreV, et al.Study on unrecognized peripheral arterial disease (PAD) by ankle/brachial index and arterial co-morbidity in Catania (Sicily, Italy). Angiology. 2010;61:524–9.
19.
ErturkMCakmakHASurgitO, et al.Predictive value of elevated neutrophil to lymphocyte ratio for long-term cardiovascular mortality in peripheral arterial occlusive disease. J Cardiol. 2014; 64: 371–376.
20.
AkkayaEGülMUğurM. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014;177:597–598.
21.
BolayirAGokceSFÇiğdemB, et al.Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol Neurochir Pol. 2018;52(2):150-155.
22.
UcarFM. A potential marker of bare metal stent restenosis: monocyte count-to-HDL cholesterol ratio. BMC Cardiovasc Disord. 2016;16:186.
23.
CanpolatUÇetinEHCetinS, et al.Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost. 2016;22(5):476-482.
24.
CetinMSOzcan CetinEHKalenderE, et al.Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ. 2016;25:1077–86.
25.
TaniSMatsumotoMAnazawaT, et al.Development of a model for prediction of coronary atherosclerotic regression: Evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count. Heart Vessels. 2012;27:143–50.
26.
KarataşMBÇangaYÖzcanKS, et al.Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with STEMI undergoing primary percutaneous coronary intervention. Am J Emergen Med. 2016;34(2):240–244.
27.
YouSZhongCZhengD, et al.Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J Neurol Sci. 2017;372:157–61.
28.
SantoroLFerraroPMFlexA, et al.New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors. Hypertens Res. 2016;39:868–73.
29.
WangXQChenJWLiC, et al.The role of monocyte to high-density lipoprotein cholesterol ratio in prediction of carotid intima media thickness in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:191.
30.
MartelloAMellisDMeloniM, et al.Phenotypic miRNA screen identifies miR-26b to promote the growth and survival of endothelial cells. Mol Ther Nucleic Acids. 2018;13:29–43.
